Compare · MOS vs NXTS
MOS vs NXTS
Side-by-side comparison of Mosaic Company (MOS) and Nexentis Technologies Inc. (NXTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MOS and NXTS operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- MOS is the larger of the two at $7.09B, about 2709.5x NXTS ($2.6M).
- Over the past year, MOS is down 38.8% and NXTS is down 97.0% - MOS leads by 58.2 points.
- NXTS has been more active in the news (5 items in the past 4 weeks vs 1 for MOS).
- MOS has more recent analyst coverage (25 ratings vs 0 for NXTS).
- Company
- Mosaic Company
- Nexentis Technologies Inc.
- Price
- $22.31+0.09%
- $1.92-9.65%
- Market cap
- $7.09B
- $2.6M
- 1M return
- +6.95%
- -67.46%
- 1Y return
- -38.79%
- -97.03%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 25
- 0
Mosaic Company
The Mosaic Company, through its subsidiaries, produces and markets concentrated phosphate and potash crop nutrients in North America and internationally. The company operates through three segments: Phosphates, Potash, and Mosaic Fertilizantes. It owns and operates mines, which produce concentrated phosphate crop nutrients, such as diammonium phosphate, monoammonium phosphate, and ammoniated phosphate products; and phosphate-based animal feed ingredients primarily under the Biofos and Nexfos brand names, as well as produces a double sulfate of potash magnesia product under K-Mag brand name. The company also produces and sells potash for use in the manufacturing of mixed crop nutrients and animal feed ingredients, and for industrial use; and for use in the de-icing and as a water softener regenerant. In addition, it provides nitrogen-based crop nutrients and animal feed ingredients, and other ancillary services; and purchases and sells phosphates, potash, and nitrogen products. The company sells its products to wholesale distributors, retail chains, farmers, cooperatives, independent retailers, and national accounts. The Mosaic Company was incorporated in 2004 and is headquartered in Tampa, Florida.
Latest MOS
- MOSAIC ANNOUNCES SECOND QUARTER 2026 EARNINGS RESULTS DATES
- SEC Form 11-K filed by Mosaic Company
- SEC Form 11-K filed by Mosaic Company
- Rothschild & Co Redburn initiated coverage on Mosaic with a new price target
- Intrepid Potash Announces Appointment of Jason Tremblay as Chief Financial Officer
- Mosaic Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Kuzenko Jody Lynne converted options into 4,873 shares, increasing direct ownership by 57% to 13,444 units (SEC Form 4)
- Director Gitzel Timothy S. converted options into 4,873 shares, increasing direct ownership by 7% to 79,527 units (SEC Form 4)
- Director Shanahan Kathleen M converted options into 4,873 shares, increasing direct ownership by 202% to 7,286 units (SEC Form 4)
- Director Watkins Gretchen H converted options into 4,873 shares, increasing direct ownership by 16% to 35,934 units (SEC Form 4)
Latest NXTS
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form EFFECT filed by Nexentis Technologies Inc.
- SEC Form S-1 filed by Nexentis Technologies Inc.
- SEC Form POS AM filed by Nexentis Technologies Inc.
- Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
- Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
- SEC Form 424B5 filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
- Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases